****

**TABLE OF CONTENTS**

[1. REPORT OVERVIEW 20](#_Toc123734726)

[1.1 Statement of the Report 22](#_Toc123734727)

[1.2 Target Demographic 24](#_Toc123734728)

[1.3 Report Sources 24](#_Toc123734729)

[1.4 Purpose of the Report 24](#_Toc123734730)

[1.4.1 Survey Recent MSC Advancements 25](#_Toc123734731)

[1.4.3 Assess Opportunities for Commercialization 25](#_Toc123734732)

[1.4.4 Identify Major Market Players & Assess the Competitive Environment 25](#_Toc123734733)

[1.4.5 Identify Existing and Emerging Trends 26](#_Toc123734734)

[1.4.6 Identify Critical Opportunities and Threats within the MSC Market 26](#_Toc123734735)

[1.5 Executive Summary 27](#_Toc123734736)

[1.6 Introduction 28](#_Toc123734737)

[2. MESENCHYMAL STEM CELLS (MSCS): AN OVERVIEW 30](#_Toc123734738)

[2.1 Stabilization of hMSCs as a Technology 30](#_Toc123734739)

[2.2 The Impact of MSCs on Regenerative Medicine 31](#_Toc123734740)

[2.3 Timeline of MSC Nomenclature 31](#_Toc123734741)

[2.4 Sources of MSCs 32](#_Toc123734742)

[2.4.1 Bone Marrow-Derived MSCs (BM-MSCs) 33](#_Toc123734743)

[2.4.2 Adipose-Derived MSCs (AD-MSCs) 34](#_Toc123734744)

[2.4.3 Umbilical Cord-Derived MSCs 34](#_Toc123734745)

[2.5 Cell Surface Markers in MSCs 35](#_Toc123734746)

[2.6 In Vitro Differentiation Potentials of MSCs 36](#_Toc123734747)

[2.7 Soluble Factors Secreted by MSCs 37](#_Toc123734748)

[2.8 Stemness Genes Present in MSCs 38](#_Toc123734749)

[3. PUBLISHED SCIENTIFIC PAPERS ON MSCS 40](#_Toc123734750)

[3.1 Number of Papers on MSCs & iPSCs Compared 41](#_Toc123734751)

[3.2 Number of Papers Published on MSC-based Clinical Trials 43](#_Toc123734752)

[3.3 Number of Papers on Clinical Trials using MSCs for Specific Diseases 44](#_Toc123734753)

[3.4 Published Papers on Modified MSCs 46](#_Toc123734754)

[3.5 Published Papers on MSC-Derived Exosomes 47](#_Toc123734755)

[4. STEM CELLS PATENT LANDSCAPE: AN OVERVIEW 49](#_Toc123734756)

[4.1 Geographical Distribution of Stem Cell Patent Filing 50](#_Toc123734757)

[4.1.1 Leading Players in Stem Cell Patent Arena 51](#_Toc123734758)

[4.1.2 Types of Patent Document Holders in Stem Cell Arena 52](#_Toc123734759)

[4.1.3 Top Ten Stem Cell Patent Owners by Size of Patent Portfolio 52](#_Toc123734760)

[4.2 MSC Patents 53](#_Toc123734761)

[4.2.1 Top Ten MSC Patent Applicants 54](#_Toc123734762)

[4.2.2 Status of MSC Patent Applications 55](#_Toc123734763)

[4.2.3 MSC Patent Jurisdictions 55](#_Toc123734764)

[4.2.4 Top Ten MSC Patent Inventors 56](#_Toc123734765)

[4.2.5 Top Ten MSC Patent Owners 57](#_Toc123734766)

[4.2.6 Patent Landscape of MSC-Derived Exosomes 57](#_Toc123734767)

[4.2.7 Number of Patent Applications by Year 58](#_Toc123734768)

[4.2.8 MSC-Exosomes Patent Jurisdiction 59](#_Toc123734769)

[4.2.9 Top Ten Patent Inventors 59](#_Toc123734770)

[5. MSCS: CLINICAL TRIAL LANDSCAPE 60](#_Toc123734771)

[5.1 Analysis of Data from ClinicalTrials.gov 60](#_Toc123734772)

[5.1.1 Sources of MSCs for Clinical Trials 62](#_Toc123734773)

[5.1.2 Autologous vs. Allogeneic MSCs in Clinical Studies 63](#_Toc123734774)

[5.1.3 Types of Funding for MSC-based Clinical Trials 64](#_Toc123734775)

[5.1.4 Types of MSC-based Clinical Trials 65](#_Toc123734776)

[5.1.5 MSC-based Clinical Trials by Phase of Development 66](#_Toc123734777)

[5.2 Administration of MSCs in Clinical Trials 67](#_Toc123734778)

[5.3 MSC Clinical Trials by Disease Category 67](#_Toc123734779)

[5.3.1 MSC-based Clinical Trials for Musculoskeletal Disorders 68](#_Toc123734780)

[5.3.2 MSC-based Clinical Trials for Neurological Disorders 69](#_Toc123734781)

[5.3.3 Clinical Trials involving MSC-derived Exosomes 70](#_Toc123734782)

[6. BIOENGINEERING SOLUTIONS TO BOOST MSC’S FUNCTIONS 73](#_Toc123734783)

[6.1 Small-Molecule Priming 73](#_Toc123734784)

[6.2 Particle Engineering 74](#_Toc123734785)

[6.3 Genetic Engineering 74](#_Toc123734786)

[6.3.1 Engineering MSCs to Go Beyond their Innate Functions 75](#_Toc123734787)

[6.3.2 Engineered MSCs for Neurological Conditions 76](#_Toc123734788)

[6.3.3 Engineered MSCs for Cardiovascular Diseases 77](#_Toc123734789)

[6.3.4 Engineered MSCs for Lung Injury 77](#_Toc123734790)

[6.3.5 Engineered MSCs for Diabetes 78](#_Toc123734791)

[6.4 Bioengineering Approaches to Improve MSC Administration 78](#_Toc123734792)

[7. MANUFACTURING OF MSCS 80](#_Toc123734793)

[7.1 Autologous and Allogeneic MSCs 80](#_Toc123734794)

[7.2 Methods of Isolation of MSCs 81](#_Toc123734795)

[7.3 Cell Expansion: Conventional Cultures to Bioreactors 82](#_Toc123734796)

[7.3.1 Monolayer Culture Systems 82](#_Toc123734797)

[7.3.2 Bioreactor-Based Cell Expansion 83](#_Toc123734798)

[7.3.2.1 Stirred Tank Bioreactor 83](#_Toc123734799)

[7.3.2.2 Rocking Bioreactor 84](#_Toc123734800)

[7.3.2.3 Hollow Fiber Bioreactors 84](#_Toc123734801)

[7.3.2.4 Fixed-Bed Bioreactors 85](#_Toc123734802)

[7.4 Bioreactors in Current Use 86](#_Toc123734803)

[7.4.1 Miniaturized Bioreactors 86](#_Toc123734804)

[7.4.2 Alternative Mixing Mechanisms 86](#_Toc123734805)

[7.5 Main Features of Commercial Bioreactors 91](#_Toc123734806)

[7.6 Number of Cells per Batch by Technologies 93](#_Toc123734807)

[7.7 Microcarriers for the Expansion of MSCs 93](#_Toc123734808)

[7.8 Downstream Processing of MSCs 96](#_Toc123734809)

[7.8.1 Cell Detachment and Separation 96](#_Toc123734810)

[7.8.2 Cell Washing and Concentration 97](#_Toc123734811)

[7.8.3 Safety & Potency Assays 97](#_Toc123734812)

[7.8.4 Surface Markers for Identification during MSC Manufacture 98](#_Toc123734813)

[7.9 Autologous & Allogeneic MSC Manufacturing: A Comparison 99](#_Toc123734814)

[7.9.1 Manufacturing Cost: Autologous and Allogeneic MSCs 100](#_Toc123734815)

[7.9.2 Cost of Manufacturing Autologous MSCs 101](#_Toc123734816)

[7.9.3 Cost of Donor Screening & Testing 101](#_Toc123734817)

[7.9.4 Cost for Release Testing 102](#_Toc123734818)

[7.10 Cost Breakdown in MSC Manufacturing 102](#_Toc123734819)

[7.10.1 Strategies for Cost Reduction 103](#_Toc123734820)

[7.10.1.1 Cost of Manufacture in Partial Automation vs. Full Automation 104](#_Toc123734821)

[7.10.1.2 CoG Breakdown in Partially-Automated MSC Manufacturing 104](#_Toc123734822)

[7.10.1.3 CoG Breakdown in Fully Automated MSC Manufacturing 105](#_Toc123734823)

[7.10.1.4 Higher Throughput in Partially Automated Facilities 106](#_Toc123734824)

[8. SMALL SCALE PROCESSING OF MSCS 108](#_Toc123734825)

[8.1 Model Design 108](#_Toc123734826)

[8.2 Culture Media 109](#_Toc123734827)

[9. LARGE-SCALE MANUFACTURING OF MSCS 114](#_Toc123734828)

[9.1 The Four Common Bioprocessing Strategies for Large-Scale Expansion of MSCs 115](#_Toc123734829)

[9.2 Commonly Used Sources of MSCs for Large-Scale Expansion 116](#_Toc123734830)

[9.3 Commonly used Culture Media for Large-Scale Expansion of MSCs 117](#_Toc123734831)

[9.3.1 Expansion Ratios Achieved with Different Culture Media 117](#_Toc123734832)

[9.4 Comparison between the Four Large-Scale MSC Expansion Strategies 119](#_Toc123734833)

[10. CONTRACT MANUFACTURING FOR CELL & GENE THERAPIES 120](#_Toc123734834)

[10.1 The Need for Staff with Expertise 120](#_Toc123734835)

[10.2 Capacity Constraints 120](#_Toc123734836)

[10.3 CDMO Platforms Showing Greatest Growth Potential 121](#_Toc123734837)

[10.4 Outsourcing Trends for Cell & Gene Therapies (CGT) 121](#_Toc123734838)

[10.4.1 Number of CDMOS Utilized by Biotechs 122](#_Toc123734839)

[10.5 CMOs/CDMOs 122](#_Toc123734840)

[10.5.1 Contract Manufacturing Organizations (CMOs) 123](#_Toc123734841)

[10.5.1.1 Major Services offered by CMOs 123](#_Toc123734842)

[10.5.2 Contract Development and Manufacturing Organizations (CDMOs) 124](#_Toc123734843)

[10.6 Global Bioprocessing Capacity 124](#_Toc123734844)

[10.6.1 Capacity Growth over Time 124](#_Toc123734845)

[10.6.2 Current Distribution of Capacity by Facility Size 126](#_Toc123734846)

[10.6.3 Global Bioprocessing Capacity by Region 126](#_Toc123734847)

[10.7 Top Global CDMOs in 2022 128](#_Toc123734848)

[10.7.1 Major Cell & Gene Therapy CDMOs in the U.S 128](#_Toc123734849)

[10.7.2 Major Cell & Gene Therapy Contract Manufacturers in Europe 129](#_Toc123734850)

[10.8 U.K.’s Domination in European Cell & Gene Therapy Contract Manufacturing 130](#_Toc123734851)

[10.8.1 Cell & Gene Therapy GMP Manufacturing in U.K. 130](#_Toc123734852)

[10.8.2 U.K. Cleanroom Footprint for CGT Manufacturing, 20018-2022 131](#_Toc123734853)

[10.8.3 Cell Therapy Process Capabilities in the U.K. by Types of Process 132](#_Toc123734854)

[10.8.4 Gene Therapy Process Capabilities in the U.K. by Types of Process 133](#_Toc123734855)

[10.8.5 Countries Importing Cell & Gene Therapy Services from U.K. 134](#_Toc123734856)

[11. MAJOR DISEASES ADDRESSED BY MSCS 136](#_Toc123734857)

[11.1 Studies using MSCs for Autoimmune Diseases 136](#_Toc123734858)

[11.2 Studies using MSCs for Cardiovascular Diseases 137](#_Toc123734859)

[11.3 Studies using MSCs for Neurodegenerative Diseases 138](#_Toc123734860)

[11.4 Studies using MSCs for Bone & Cartilage Diseases 139](#_Toc123734861)

[11.5 Studies using MSCs in GvHD 140](#_Toc123734862)

[11.6 Studies using MSCs in Crohn’s Disease 141](#_Toc123734863)

[11.7 Studies using MSCs in Type 1 Diabetes 142](#_Toc123734864)

[11.8 Studies using MSCS in Systemic Lupus Erythematosus (SLE) 142](#_Toc123734865)

[11.9 Studies using MSCs in Parkinson’s disease (PD) 143](#_Toc123734866)

[11.10 Studies using MSCs in Alzheimer’s Disease (AD) 143](#_Toc123734867)

[11.11 Studies using MSCs in Kidney Failure 144](#_Toc123734868)

[11.12 Studies using MSCs in Spinal Cord Injury (SCI) 144](#_Toc123734869)

[11.13 MSCs for Chronic Wounds 145](#_Toc123734870)

[12. CURRENT STATUS OF MESENCHYMAL STEM CELL INDUSTRY 146](#_Toc123734871)

[12.1 Brief Account of Modified MSCs 146](#_Toc123734872)

[12.1.1 Genetic Modification of MSCs 147](#_Toc123734873)

[12.1.2 Priming of MSCs 148](#_Toc123734874)

[12.1.2.1 Primed MSCs in Clinical Trials 148](#_Toc123734875)

[12.1.3 Biomaterial Strategies 149](#_Toc123734876)

[12.1.4 MSC Secretomes 150](#_Toc123734877)

[12.1.5 MSCs in Topical Cosmetics 151](#_Toc123734878)

[12.1.5.1 Cosmetic Effects of Secretomes 151](#_Toc123734879)

[12.1.5.2 Secretome-Based Formulations for Skincare 152](#_Toc123734880)

[12.2 MSC-Based Products with Marketing Approval 155](#_Toc123734881)

[12.2.1 Alofisel 156](#_Toc123734882)

[12.2.2 Stemirac 157](#_Toc123734883)

[12.2.3 Stempeucel 157](#_Toc123734884)

[12.2.4 Temcell HS 158](#_Toc123734885)

[12.2.5 Neuronata-R 158](#_Toc123734886)

[12.2.6 Prochymal 158](#_Toc123734887)

[12.2.7 Cupistem 159](#_Toc123734888)

[12.2.8 Cartistem 159](#_Toc123734889)

[12.2.9 Cellgram-AMI 159](#_Toc123734890)

[12.2.10 Queencell 159](#_Toc123734891)

[12.3 Currently Marketed MSC-Based Bone Matrices 160](#_Toc123734892)

[12.3.1 Osteocel 161](#_Toc123734893)

[12.3.2 AlloStem 161](#_Toc123734894)

[12.3.3 Cellentra VCBM 161](#_Toc123734895)

[12.3.4 HiQCell 162](#_Toc123734896)

[12.3.5 Trinity ELITE 162](#_Toc123734897)

[12.3.6 Map3 162](#_Toc123734898)

[12.3.7 Trinity Evolution 163](#_Toc123734899)

[12.3.8 Carticel 163](#_Toc123734900)

[12.3.9 Chondron 163](#_Toc123734901)

[12.3.10 DeNovo 163](#_Toc123734902)

[12.3.11 Chondrocelect 164](#_Toc123734903)

[12.3.12 Ossron 164](#_Toc123734904)

[12.3.13 JACC 164](#_Toc123734905)

[12.3.14 MACI 165](#_Toc123734906)

[12.3.15 Ortho-ACI 165](#_Toc123734907)

[12.3.16 Spherox 165](#_Toc123734908)

[12.3.17 Ossgrow 166](#_Toc123734909)

[12.3.18 Cartigrow 166](#_Toc123734910)

[12.3.19 ViviGen 166](#_Toc123734911)

[12.3.20 Bio4 166](#_Toc123734912)

[12.3.21 Cartiform 167](#_Toc123734913)

[13. RECENT COLLABORATIONS IN MSC SECTOR 168](#_Toc123734914)

[13.1 RoosterBio’s Partnership with AGC Biologics 168](#_Toc123734915)

[13.2 RoosterBio’s Partnership with ShiftBio 168](#_Toc123734916)

[13.3 Pluristem’s Collaboration with Tnuva Group 169](#_Toc123734917)

[13.4 RoosterBio’s Partnership with Univercells Technologies 169](#_Toc123734918)

[13.5 Partnership between Cynata & Fujifilm 169](#_Toc123734919)

[13.6 Collaboration between American CryoStem Corp. & BioTherapeutic Labs Corp 170](#_Toc123734920)

[13.7 RoosterBio’s Partnership with Sartorius 170](#_Toc123734921)

[13.8 Research & Development Agreement between American CryoStem and CRADA 171](#_Toc123734922)

[13.9 RoosterBio’s Partnership with Sartorius Korea Biotech 171](#_Toc123734923)

[13.10 Partnership between Catalent and BrainStorm 172](#_Toc123734924)

[13.11 Collaboration between Cipla & Stempeutics 172](#_Toc123734925)

[13.12 Aethlon’s Collaboration with University of Pittsburgh 172](#_Toc123734926)

[13.13 RoosterBio’s Partnership with Senti Biosciences 173](#_Toc123734927)

[14. MARKET ANALYSIS 174](#_Toc123734928)

[14.2 Price Tags of MSC-Based CT Treatment 175](#_Toc123734929)

[14.3 Price Tags of MSC-Based Matrices 177](#_Toc123734930)

[14.4 Market Size of MSC-Based Therapies 178](#_Toc123734931)

[14.5 Global Market for MSC-Based Therapeutics 179](#_Toc123734932)

[14.6 Global Demand for Mesenchymal Stem Cells (MSCs) 181](#_Toc123734933)

[14.6.1 Global Demand for MSCs in Academic and Preclinical Studies 181](#_Toc123734934)

[14.6.2 Global Demand for MSCs in Clinical Trials 181](#_Toc123734935)

[14.6.3 Global Demand for MSCs for the Development of Therapeutics 181](#_Toc123734936)

[14.6.4 Global Demand for MSCs to Develop Exosome Products 182](#_Toc123734937)

[14.6.5 Global Demand for MSCs in Emerging Industries 182](#_Toc123734938)

[14.6.6 Global Market for MSCs 182](#_Toc123734939)

[14.6.7 Market Share of MSC-Based Business Segments 184](#_Toc123734940)

[15. COMPANY PROFILES 186](#_Toc123734941)

[15.1 101 Bio 186](#_Toc123734942)

[15.1.2 Products 186](#_Toc123734943)

[15.1.3 Services 187](#_Toc123734944)

[15.2 AbbVie, Inc. 188](#_Toc123734945)

[15.2.1 SkinMedica Neck Correct Cream 188](#_Toc123734946)

[15.3 Abzena 189](#_Toc123734947)

[15.3.1 Services 189](#_Toc123734948)

[15.4 Adipomics, Inc. 190](#_Toc123734949)

[15.5 Advancells 191](#_Toc123734950)

[15.5.1 MSC-Derived Exosome Therapy 191](#_Toc123734951)

[15.6 Advent BioServices, Ltd. 192](#_Toc123734952)

[15.6.1 Ultra Cold Storage Services 192](#_Toc123734953)

[15.6.2 Quality Control Services 192](#_Toc123734954)

[15.7 Aegle Therapeutics 193](#_Toc123734955)

[15.7.1 Aegle’s Platform Technology 193](#_Toc123734956)

[15.7.2 Epidermolysis Bullosa 193](#_Toc123734957)

[15.8 Aethlon Medical, Inc. 194](#_Toc123734958)

[15.8.1 Hemopurifier in Infectious Disease 194](#_Toc123734959)

[15.8.2 Status of Clinical Studies 195](#_Toc123734960)

[15.8.3 Hemopurifier in Cancer 195](#_Toc123734961)

[15.9 AGC Biologics 196](#_Toc123734962)

[15.9.1 Offerings 196](#_Toc123734963)

[15.10 AgeX Therapeutics, Inc. 197](#_Toc123734964)

[15.10.1 Pluristem Technology 197](#_Toc123734965)

[15.10.2 Induced Tissue Generation 197](#_Toc123734966)

[15.10.3 UniverCyte 198](#_Toc123734967)

[15.10.4 HyStem Delivery Technology 198](#_Toc123734968)

[15.11 AlloSource, Inc. 199](#_Toc123734969)

[15.11.1 Allografts with Tissue-derived MSCs 199](#_Toc123734970)

[15.11.2 Products 199](#_Toc123734971)

[15.11.2.1 AlloConnex 199](#_Toc123734972)

[15.11.2.2 AlloFuse & AlloFuse Plus DBM 200](#_Toc123734973)

[15.11.2.3 AlloFlex Plus 200](#_Toc123734974)

[15.11.2.4 AlloFuse Cervical Grafts 200](#_Toc123734975)

[15.11.2.5 AlloFuse Fiber and Fiber Boats 201](#_Toc123734976)

[15.11.2.6 AlloFuse Select CM 201](#_Toc123734977)

[15.12 Ambulero 202](#_Toc123734978)

[15.12.1 Supercharged MSCs 202](#_Toc123734979)

[15.12.2 Ambulero’s Pipeline 202](#_Toc123734980)

[15.13 American CryoStem Corporation 203](#_Toc123734981)

[15.13.1 Products 203](#_Toc123734982)

[15.13.1.1 CELLECT Tissue Harvesting System 203](#_Toc123734983)

[15.13.1.2 ACSelerateMAX hMSC Medium 203](#_Toc123734984)

[15.13.1.3 ATCELL Mesenchymal Stem Cells (ADSCs) 204](#_Toc123734985)

[15.13.2 Services 204](#_Toc123734986)

[15.13.2.1 ATGRAFT Fat Storage 204](#_Toc123734987)

[15.13.2.2 Adult Stem Cell Program 204](#_Toc123734988)

[15.14 American Type Culture Collection (ATCC) 205](#_Toc123734989)

[15.14.1 Stem Cell Products 205](#_Toc123734990)

[15.15 AMS Biotechnology, Ltd. (AMSBIO) 206](#_Toc123734991)

[15.15.1 Products 206](#_Toc123734992)

[15.16 Andelyn Biosciences 207](#_Toc123734993)

[15.16.1 Andelyn’s Solutions 207](#_Toc123734994)

[15.17 Anemocyte S.r.l 208](#_Toc123734995)

[15.17.1 Total GMP Capacity 208](#_Toc123734996)

[15.17.2 Product Types 208](#_Toc123734997)

[15.17.3 Manufacturing Services 208](#_Toc123734998)

[15.18 Anterogen, Co., Ltd. 209](#_Toc123734999)

[15.18.1 Products 209](#_Toc123735000)

[15.18.1.1 Cupistem Injection 209](#_Toc123735001)

[15.18.1.2 Queencell Injection 210](#_Toc123735002)

[15.19 AQ Skin Solutions 210](#_Toc123735003)

[15.19.1 Products 210](#_Toc123735004)

[15.19.1.1 AQ Active Serum 210](#_Toc123735005)

[15.19.1.2 AQ Eye Serum 211](#_Toc123735006)

[15.19.1.3 AQ Lash 211](#_Toc123735007)

[15.19.1.4 AQ Vaginal Rejuvenation System 211](#_Toc123735008)

[15.20 Arranta Bio 212](#_Toc123735009)

[15.20.1 Services 212](#_Toc123735010)

[15.21 Aruna Bio 213](#_Toc123735011)

[15.21.1 AB126 213](#_Toc123735012)

[15.22 Avid Bioservices, Inc. 214](#_Toc123735013)

[15.22.1 Services 214](#_Toc123735014)

[15.23 Bacthera 215](#_Toc123735015)

[15.23.1 Services 215](#_Toc123735016)

[15.24 Baylx, Inc. 216](#_Toc123735017)

[15.24.1 Technology 216](#_Toc123735018)

[15.24.2 Rheumatoid Arthritis 216](#_Toc123735019)

[15.24.3 Metastatic Cancer 216](#_Toc123735020)

[15.24.4 FDA Clearance of IND Application 217](#_Toc123735021)

[15.25 BioCardia 218](#_Toc123735022)

[15.25.1 BioCardia’s Pipeline Overview 218](#_Toc123735023)

[15.25.1.1 CardiAMP Cell Therapy 218](#_Toc123735024)

[15.25.1.2 CardiALLO Cell Therapy 219](#_Toc123735025)

[15.26 BioCentriq 220](#_Toc123735026)

[15.26.1 Clinical Manufacturing Services 220](#_Toc123735027)

[15.26.2 Process Development Services 220](#_Toc123735028)

[15.27 BioEden, Inc. 221](#_Toc123735029)

[15.28 Bioinova s.r.o 221](#_Toc123735030)

[15.28.1 MSCs for Clinical Trials 221](#_Toc123735031)

[15.28.2 Novel Solution for Storage and Transportation of Cells 222](#_Toc123735032)

[15.29 BioRestorative Therapies 223](#_Toc123735033)

[15.29.1 BRTX-100 223](#_Toc123735034)

[15.29.2 ThermoStem 223](#_Toc123735035)

[15.30 Bioscience Institute S.p.A 224](#_Toc123735036)

[15.30.1 LIPOSKILL 224](#_Toc123735037)

[15.30.2 HAIRSKILL 224](#_Toc123735038)

[15.30.3 GYNSKILL 224](#_Toc123735039)

[15.30.4 LIPOSKILL PLUS 225](#_Toc123735040)

[15.31 Bio-Techne 225](#_Toc123735041)

[15.31.1 Mesenchymal Stem Cell Products 225](#_Toc123735042)

[15.32 Blue Horizon International, LLC 226](#_Toc123735043)

[15.32.1 BHI’s Stem Cell Division 226](#_Toc123735044)

[15.33 Boehringer Ingelheim BioXcellence 227](#_Toc123735045)

[15.33.1 Services 227](#_Toc123735046)

[15.33.2 Cell Line Development Services 227](#_Toc123735047)

[15.34 Bonus Biogroup, Ltd. 228](#_Toc123735048)

[15.34.1 BonoFill 228](#_Toc123735049)

[15.34.2 MesenCure 228](#_Toc123735050)

[15.35 BrainStorm Cell Therapeutics 229](#_Toc123735051)

[15.35.1 MSC-NTF Cells 229](#_Toc123735052)

[15.36 Caregen Nordic 230](#_Toc123735053)

[15.36.1 Dermaheal HSR 230](#_Toc123735054)

[15.36.2 Dermaheal HL 230](#_Toc123735055)

[15.36.3 Dermaheal SB 231](#_Toc123735056)

[15.36.4 Dermaheal Stem C’rum 231](#_Toc123735057)

[15.36.5 Dermaheal Stem C’rum SR 231](#_Toc123735058)

[15.37 CardioCell, LLC 232](#_Toc123735059)

[15.37.1 The itMSC Advantage 232](#_Toc123735060)

[15.37.2 Clinical Trials 232](#_Toc123735061)

[15.38 Catalent Pharma Solutions 233](#_Toc123735062)

[15.38.1 OneBio Integrated Suite 233](#_Toc123735063)

[15.38.2 Gene Therapy Services 233](#_Toc123735064)

[15.38.3 Cell Therapy Services 234](#_Toc123735065)

[15.39 CCRM 234](#_Toc123735066)

[15.39.1 CDMO Services 234](#_Toc123735067)

[15.40 Cellipont Bioservices 235](#_Toc123735068)

[15.40.1 Cellipont’s Capabilities 235](#_Toc123735069)

[15.40.2 Cellipont’s Cell Expertise 236](#_Toc123735070)

[15.41 Celprogen, Inc. 237](#_Toc123735071)

[15.41.1 Products 237](#_Toc123735072)

[15.41.1.1 FolliStem 237](#_Toc123735073)

[15.41.1.2 FolliStem Jawan 237](#_Toc123735074)

[15.42 CellResearch Corporation, Pte Ltd. 238](#_Toc123735075)

[15.42.1 Umbilical Cord Lining Stem Cells 238](#_Toc123735076)

[15.43 Celltex Therapeutics Corporation 239](#_Toc123735077)

[15.43.1 Therapy Services 239](#_Toc123735078)

[15.44 Cellular Biomedicine Group, Inc. 240](#_Toc123735079)

[15.45 Citius Pharmaceuticals, Inc. 241](#_Toc123735080)

[15.45.1 Stem Cell Platform 241](#_Toc123735081)

[15.46 Charles River Laboratories International, Inc. 242](#_Toc123735082)

[15.46.1 Products & Services 242](#_Toc123735083)

[15.47 Corestem, Inc. 243](#_Toc123735084)

[15.47.1 ALS (NeuroNata-R) 243](#_Toc123735085)

[15.48 Creative Bioarray 244](#_Toc123735086)

[15.48.1 MSC Services 244](#_Toc123735087)

[15.48.1.1 MSC Isolation and Expansion Services 244](#_Toc123735088)

[15.48.1.2 MSC Characterization Service 245](#_Toc123735089)

[15.48.1.3 MSC Differentiation Service 245](#_Toc123735090)

[15.49 Curia Global, Inc. 246](#_Toc123735091)

[15.49.1 Services 246](#_Toc123735092)

[15.50 Cynata Therapeutics, Ltd. 247](#_Toc123735093)

[15.50.1 Cymerus Platform 247](#_Toc123735094)

[15.50.1.1 Importance of Cymerus Technology 247](#_Toc123735095)

[15.50.2 Preclinical Development 248](#_Toc123735096)

[15.50.2.1 GvHD 248](#_Toc123735097)

[15.50.2.2 Critical Limb Ischemia 248](#_Toc123735098)

[15.50.2.3 Asthma 248](#_Toc123735099)

[15.50.2.4 Heart Attack 249](#_Toc123735100)

[15.50.2.5 Diabetic Wounds 249](#_Toc123735101)

[15.50.2.6 Coronary Artery Disease (CAD) 249](#_Toc123735102)

[15.50.2.7 Acute Respiratory Distress Syndrome (ARDS) 249](#_Toc123735103)

[15.50.2.8 Sepsis 250](#_Toc123735104)

[15.50.2.9 Osteoarthritis 250](#_Toc123735105)

[15.51 Cytovance Biologics 251](#_Toc123735106)

[15.51.1 CGMP Manufacturing 251](#_Toc123735107)

[15.52 Dendreon 252](#_Toc123735108)

[15.52.1 Provenge Immunotherapy 252](#_Toc123735109)

[15.52.2 Services 252](#_Toc123735110)

[15.53 Direct Biologics 253](#_Toc123735111)

[15.53.1 ExoFlo 253](#_Toc123735112)

[15.54 ElevateBio 254](#_Toc123735113)

[15.54.1 ElevateBio’s Enabling Technologies 254](#_Toc123735114)

[15.54.2 BaseCamp cGMP 255](#_Toc123735115)

[15.55 Exothera 256](#_Toc123735116)

[15.55.1 Exoscan Process Analysis Services 256](#_Toc123735117)

[15.55.2 Process Design & Development Services 256](#_Toc123735118)

[15.55.3 GMP Manufacturing Services 257](#_Toc123735119)

[15.56 EXOSOMEplus 258](#_Toc123735120)

[15.57 FUJIFILM Cellular Dynamics, Inc. 259](#_Toc123735121)

[15.57.1 iCell Mesenchymal Stem Cells 259](#_Toc123735122)

[15.58 Fujifilm Diosynth Biotechnologies 260](#_Toc123735123)

[15.58.1 Cell & Gene Therapy Services 260](#_Toc123735124)

[15.59 Future Cell Japan Co., Ltd. 261](#_Toc123735125)

[15.59.1 BABY STEM 261](#_Toc123735126)

[15.60 Genezen 262](#_Toc123735127)

[15.60.1 Genezen’s Capabilities 262](#_Toc123735128)

[15.61 Hope Biosciences, LLC 264](#_Toc123735129)

[15.61.1 Adult Stem Cell Banking 264](#_Toc123735130)

[15.61.2 Newborn Stem Cell Banking 264](#_Toc123735131)

[15.61.3 Hope Sponsored Clinical Trials 264](#_Toc123735132)

[15.62 Invitrx Therapeutics 266](#_Toc123735133)

[15.62.1 Reluma 266](#_Toc123735134)

[15.63 JCR Pharmaceuticals, Co., Ltd. 267](#_Toc123735135)

[15.63.1 TEMCELL HS Inj. 267](#_Toc123735136)

[15.64 Just-Evotec Biologics, Inc. 268](#_Toc123735137)

[15.64.1 J.POD Biomanufacturing Facility 268](#_Toc123735138)

[15.64.2 J.Design Solutions 268](#_Toc123735139)

[15.64.3 J.DISCOVERY – Molecule Discovery 268](#_Toc123735140)

[15.64.4 J.MD – Molecule Design 269](#_Toc123735141)

[15.64.5 JP3 – Process & Product Design 269](#_Toc123735142)

[15.64.6 J-POD – Manufacturing Design 269](#_Toc123735143)

[15.65 Kimera Labs, Inc. 270](#_Toc123735144)

[15.65.1 XoGlo 270](#_Toc123735145)

[15.65.2 XoGlo Pro 270](#_Toc123735146)

[15.65.3 Equisome HC 272](#_Toc123735147)

[15.65.4 Vive 272](#_Toc123735148)

[15.65.4.1 Effects of MSC Exosomes on Skin 272](#_Toc123735149)

[15.66 LifeCell 273](#_Toc123735150)

[15.66.1 Large-Scale Manufacturing of MSCs 273](#_Toc123735151)

[15.67 Longeveron 274](#_Toc123735152)

[15.67.1 Lomecel-B 274](#_Toc123735153)

[15.67.2 Focused Therapeutic Areas 274](#_Toc123735154)

[15.67.2.1 Hypoplastic Left Heart Syndrome (HLHS) Research Program 275](#_Toc123735155)

[15.67.2.2 Alzheimer’s disease (AD) Research Program 275](#_Toc123735156)

[15.67.2.3 Aging Frailty Research Program 275](#_Toc123735157)

[15.67.2.4 Metabolic Syndrome Research Program 275](#_Toc123735158)

[15.67.2.5 Acute Respiratory Distress Syndrome (ARDS) Research Program 276](#_Toc123735159)

[15.68 Lonza Group, Ltd. 277](#_Toc123735160)

[15.68.1 Product Overview 277](#_Toc123735161)

[15.68.1.1 Poietics 277](#_Toc123735162)

[15.68.1.2 MSCGM Growth Medium 278](#_Toc123735163)

[15.68.1.3 TheraPEAK Growth Medium 278](#_Toc123735164)

[15.68.1.4 hMSC Chondrogenic Differentiation Medium 278](#_Toc123735165)

[15.68.1.5 hMSC Adipogenic Differentiation Medium 278](#_Toc123735166)

[15.68.1.6 ReagentPack Subculture Reagents 279](#_Toc123735167)

[15.68.1.7 Trypsin/EDTA for Mesenchymal Stem Cells 279](#_Toc123735168)

[15.69 Lorem Cytori USA, Inc. 280](#_Toc123735169)

[15.69.1 Celution System 280](#_Toc123735170)

[15.70 Lykan Bioscience 281](#_Toc123735171)

[15.70.1 Process Development 281](#_Toc123735172)

[15.70.2 Analytical Development 281](#_Toc123735173)

[15.70.3 Manufacturing Science & Technology 282](#_Toc123735174)

[15.70.4 Clinical & Commercial Manufacturing 282](#_Toc123735175)

[15.70.5 Supply Chain & Logistics 283](#_Toc123735176)

[15.70.6 Quality & Compliance 283](#_Toc123735177)

[15.71 Matica Biotechnology, Inc. 284](#_Toc123735178)

[15.71.1 Cell Line Development Services 284](#_Toc123735179)

[15.71.2 Process Development Services 284](#_Toc123735180)

[15.71.3 Assay Development Services 284](#_Toc123735181)

[15.71.4 GMP Production Services 285](#_Toc123735182)

[15.71.5 Product Release & Stability Testing 285](#_Toc123735183)

[15.72 Medipost, Co., Ltd. 286](#_Toc123735184)

[15.72.1 Products 286](#_Toc123735185)

[15.72.1.1 Cartistem 286](#_Toc123735186)

[15.72.1.2 Pneumostem 286](#_Toc123735187)

[15.72.1.3 SMUP-IA-01 287](#_Toc123735188)

[15.72.1.4 SMUP-IV-01 287](#_Toc123735189)

[15.73 Mesoblast, Ltd. 288](#_Toc123735190)

[15.73.1 Product Candidates 288](#_Toc123735191)

[15.73.1.1 Remestemcel-L 289](#_Toc123735192)

[15.73.1.2 Rexlemestrocel-L 289](#_Toc123735193)

[15.74 MilliporeSigma 290](#_Toc123735194)

[15.74.1 Cell Culture & Analysis Products 290](#_Toc123735195)

[15.75 NecstGen 292](#_Toc123735196)

[15.75.1 Cell Therapy Development & Manufacturing 292](#_Toc123735197)

[15.75.2 Viral Vector Development & Manufacturing 293](#_Toc123735198)

[15.75.3 Cleanroom Rental 293](#_Toc123735199)

[15.76 Novus Biologicals, LLC 294](#_Toc123735200)

[15.77 NuVasive, Inc. 295](#_Toc123735201)

[15.77.1 Osteocel Family 295](#_Toc123735202)

[15.78 OCT Therapies & Research Pvt. Ltd. 296](#_Toc123735203)

[15.79 Orthofix Medical, Inc. 297](#_Toc123735204)

[15.79.1 Trinity ELITE 297](#_Toc123735205)

[15.79.2 TrinityEvolution 297](#_Toc123735206)

[15.80 Personal Cell Sciences, Corp. 298](#_Toc123735207)

[15.80.1 Autokine CM 298](#_Toc123735208)

[15.80.2 Products 298](#_Toc123735209)

[15.80.2.1 U Autologous Adult Stem Cell Regenerative Firming Serum 298](#_Toc123735210)

[15.80.2.2 U Autologous Adult Stem Cell Regenerative Eye Cream 299](#_Toc123735211)

[15.80.2.3 U Autologous Adult Stem Cell Regenerative Moisturizer 299](#_Toc123735212)

[15.81 Personalized Stem Cells, Inc. 300](#_Toc123735213)

[15.81.1 Personalized Stem Cell Study: Knee Osteoarthritis 300](#_Toc123735214)

[15.82 Porton Advanced 301](#_Toc123735215)

[15.82.1 Cell Therapy Services 301](#_Toc123735216)

[15.82.2 Portons LVV Services 301](#_Toc123735217)

[15.83 Pluristem Therapeutics, Inc. 302](#_Toc123735218)

[15.83.1 PLX Products 302](#_Toc123735219)

[15.83.2 PLX-PAD 303](#_Toc123735220)

[15.83.2.1 Mechanism of Action 303](#_Toc123735221)

[15.83.3 PLX-R18 303](#_Toc123735222)

[15.83.3.1 Mechanism of Action 304](#_Toc123735223)

[15.83.4 PLX-Immune 304](#_Toc123735224)

[15.83.4.1 Mechanism of Action 304](#_Toc123735225)

[15.84 PromoCell GmbH 305](#_Toc123735226)

[15.84.1 Human Stem & Blood Cell Culture Products 305](#_Toc123735227)

[15.85 Regeneus, Ltd. 306](#_Toc123735228)

[15.85.1 Technologies 306](#_Toc123735229)

[15.85.1.1 Progenza 306](#_Toc123735230)

[15.85.1.1.1 Mechanism of Action 306](#_Toc123735231)

[15.85.1.2 Sygenus 307](#_Toc123735232)

[15.85.1.2.1 Mechanism of Action 307](#_Toc123735233)

[15.85.2 Product Pipeline 307](#_Toc123735234)

[15.86 Reliance Life Sciences Pvt. Ltd. 308](#_Toc123735235)

[15.86.1 Regenerative Medicine Products 308](#_Toc123735236)

[15.87 Rentschler Biopharma 309](#_Toc123735237)

[15.87.1 Services 309](#_Toc123735238)

[15.88 Resilience 310](#_Toc123735239)

[15.88.1 Resilience’s Capabilities 310](#_Toc123735240)

[15.89 Richter-HELM 311](#_Toc123735241)

[15.89.1 Services 311](#_Toc123735242)

[15.90 RoosterBio, Inc. 312](#_Toc123735243)

[15.90.1 RoosterBio’s Technology 312](#_Toc123735244)

[15.90.2 Products 312](#_Toc123735245)

[15.90.2.1 Human Mesenchymal Stem Cells (hMSCs) 313](#_Toc123735246)

[15.90.3 Genetic Engineering Tools 313](#_Toc123735247)

[15.90.3.1 Genetic Engineering Media 314](#_Toc123735248)

[15.90.3.2 Cell Culture Media & Supplements 314](#_Toc123735249)

[15.90.4 Cell and Media Kits 315](#_Toc123735250)

[15.90.5 MSC-derived Exosomes 316](#_Toc123735251)

[15.90.6 cGMP CliniControl Products 316](#_Toc123735252)

[15.90.7 Process Development Services 317](#_Toc123735253)

[15.90.8 hMSC Analytical Services 318](#_Toc123735254)

[15.91 RoslinCT 319](#_Toc123735255)

[15.91.1 Services 319](#_Toc123735256)

[15.91.1.1 Process Development 319](#_Toc123735257)

[15.91.1.2 GMP Manufacturing 320](#_Toc123735258)

[15.91.1.3 Quality Control 320](#_Toc123735259)

[15.91.1.4 Quality & Regulations 320](#_Toc123735260)

[15.91.1.5 Product Storage & Logistics 320](#_Toc123735261)

[15.91.2 RoslinCT – Lykan Bioscience Combine 321](#_Toc123735262)

[15.92 Samsung Biologics 321](#_Toc123735263)

[15.92.1 Development Services 321](#_Toc123735264)

[15.92.2 Manufacturing Services 321](#_Toc123735265)

[15.93 Sentien Biotechnologies, Inc. 322](#_Toc123735266)

[15.93.1 SBI-101 322](#_Toc123735267)

[15.93.1.1 Prolonged Therapeutic Activity of MSCs in SBI-101 322](#_Toc123735268)

[15.93.1.2 Sentien’s Product Pipeline 323](#_Toc123735269)

[15.94 Smith & Nephew plc 324](#_Toc123735270)

[15.94.1 Grafix 324](#_Toc123735271)

[15.95 STEMCELL Technologies, Inc. 325](#_Toc123735272)

[15.95.1 Products 325](#_Toc123735273)

[15.95.1.1 Mesenchymal Stem Cells (MSCs) 325](#_Toc123735274)

[15.95.1.2 Mesenchymal Stem and Progenitor Cell Research Products 325](#_Toc123735275)

[15.96 Stemedica Cell Technologies, Inc. 326](#_Toc123735276)

[15.96.1 BioSmart Technology 326](#_Toc123735277)

[15.96.2 Clinical Pipeline 327](#_Toc123735278)

[15.97 Stemmatters 328](#_Toc123735279)

[15.98 Stempeutics Research Pvt. Ltd. 329](#_Toc123735280)

[15.98.1 Stempeucel 329](#_Toc123735281)

[15.98.1.1 Process Description 329](#_Toc123735282)

[15.98.2 Stempeucare 330](#_Toc123735283)

[15.98.3 Cutisera 330](#_Toc123735284)

[15.98.4 Trichosera 330](#_Toc123735285)

[15.98.5 Perioptisera 330](#_Toc123735286)

[15.99 Syngene International Ltd. 331](#_Toc123735287)

[15.99.1 Services 331](#_Toc123735288)

[15.100 TaiwanBio Therapeutics, Co., Ltd. 332](#_Toc123735289)

[15.101 Takeda Pharmaceutical Co., Ltd. 333](#_Toc123735290)

[15.101.1 Alofisel (Darvadstrocel) 333](#_Toc123735291)

[15.102 Symbiosis Pharmaceutical Services 334](#_Toc123735292)

[15.102.1 Vial Filling Capability 334](#_Toc123735293)

[15.102.2 Drug Product Testing 334](#_Toc123735294)

[15.102.3 Qualified Person Release 335](#_Toc123735295)

[15.102.4 Clinical Labeling & Packaging 335](#_Toc123735296)

[15.102.5 Product Development 335](#_Toc123735297)

[15.103 Tempo Bioscience 336](#_Toc123735298)

[15.103.1 Products 336](#_Toc123735299)

[15.103.1.1 Human Cell Models 336](#_Toc123735300)

[15.103.2 Services & Alliances 336](#_Toc123735301)

[15.104 Thermo Fisher Scientific 337](#_Toc123735302)

[15.104.1 Cell Culture Services 337](#_Toc123735303)

[15.104.2 Cell Therapy Solutions 338](#_Toc123735304)

[15.105 TranstoxBio 339](#_Toc123735305)

[15.105.1 Products 339](#_Toc123735306)

[15.105.1.1 CarcinogenSAFE 339](#_Toc123735307)

[15.105.1.2 CardioSight 339](#_Toc123735308)

[15.105.1.3 HeMOToX 340](#_Toc123735309)

[15.105.1.4 HepatoSight 340](#_Toc123735310)

[15.105.1.5 NeuroSAFE 340](#_Toc123735311)

[15.105.1.6 SkinIR System 340](#_Toc123735312)

[15.105.1.7 TransD System 340](#_Toc123735313)

[15.105.1.8 Human Umbilical Cord Blood Monocytes 341](#_Toc123735314)

[15.105.1.9 Human Peripheral Blood CD34 Positive Cells 341](#_Toc123735315)

[15.105.1.10 CD34+ Configured Cellular Platform 341](#_Toc123735316)

[15.105.1.11 Human Mesenchymal Stem Cells 341](#_Toc123735317)

[15.106 United Therapeutics Corporation 342](#_Toc123735318)

[15.106.1 Genetically-Enhanced Mesenchymal Stem Cells (GEM) 342](#_Toc123735319)

[15.107 Viralgen 343](#_Toc123735320)

[15.107.1 Service 343](#_Toc123735321)

[15.107.2 Viralgen’s Facilities 343](#_Toc123735322)

[15.108 VIVEbiotech 344](#_Toc123735323)

[15.109 Waisman Biomanufacturing 345](#_Toc123735324)

[15.109.1 GMP Cell Therapeutic Capabilities 345](#_Toc123735325)

[15.109.2 Cell Bank Specifics 345](#_Toc123735326)

[15.109.3 Waisman Products & Processes 346](#_Toc123735327)

[15.110 WuXi Biologics 346](#_Toc123735328)

[15.110.1 Manufacturing Services 346](#_Toc123735329)

[15.111 Yapan Bio 347](#_Toc123735330)

[15.111.1 Process Development Services 347](#_Toc123735331)

[15.111.2 Process Characterization Services 348](#_Toc123735332)

[15.111.3 GMP Manufacturing Services 348](#_Toc123735333)

[15.112 Yposkesi 349](#_Toc123735334)

[15.113 Zimmer Biomet Holdings, Inc. 350](#_Toc123735335)

[15.113.1 Cellentra VCBM 350](#_Toc123735336)

**INDEX OF FIGURES**

[FIGURE 3.1: Number of Published Papers on MSCs between 2000 and 2022 41](#_Toc123735338)

[FIGURE 3.2: Number of Papers on MSCs & iPSCs Compared 42](#_Toc123735339)

[FIGURE 3.3: Number of Papers Published on MSC-based Clinical Trials, 2000-2022 44](#_Toc123735340)

[FIGURE 3.4: Percent Share of Papers on Clinical Trials for Specific Diseases, 2000-2022 45](#_Toc123735341)

[FIGURE 3.5: Number of Published Papers on Modified MSCs 47](#_Toc123735342)

[FIGURE 3.6: Number of PubMed Papers on MSC-Exosomes 48](#_Toc123735343)

[FIGURE 4.1: Number of Patent Documents in Stem Cell Therapies, 2011-2020 50](#_Toc123735344)

[FIGURE 4.2: Geographical/Country Distribution of Stem Cell Patents 51](#_Toc123735345)

[FIGURE 4.3: Types of Patent Document Holders in Stem Cell Arena 52](#_Toc123735346)

[FIGURE 4.4: Number of MSC Patent Filings by Year, 2000-January 5, 2023 54](#_Toc123735347)

[FIGURE 4.5: Number of MSC-Exosomes Patent Applications by Year, 2009 to Present 58](#_Toc123735348)

[FIGURE 5.1: Number of Clinical Trials involving MSCs by Region 61](#_Toc123735349)

[FIGURE 5.2: Sources of MSCs for Clinical Trials in 2022 62](#_Toc123735350)

[FIGURE 5.3: Clinical Trials involving Autologous and Allogeneic MSCs in 2022 63](#_Toc123735351)

[FIGURE 5.4: Types of Funding for MSC-based Clinical Trials 64](#_Toc123735352)

[FIGURE 5.5: Types of MSC-based Clinical Trials 65](#_Toc123735353)

[FIGURE 5.6: MSC-based Clinical Trials by Phase of Development 66](#_Toc123735354)

[FIGURE 5.7: MSC Administration Routes 67](#_Toc123735355)

[FIGURE 5.8: MSC Clinical Trials by Disease Category 68](#_Toc123735356)

[FIGURE 6.1: Bioengineering Solutions to Boost the Functions of MSCs 73](#_Toc123735357)

[FIGURE 6.2: Bioengineering Solutions for Improving Administration of MSCs 79](#_Toc123735358)

[FIGURE 7.1: Advantages & Disadvantages of Autologous & Allogeneic MSCs 80](#_Toc123735359)

[FIGURE 7.2: Monolayer Culture Systems 82](#_Toc123735360)

[FIGURE 7.3: Stirred Tank Bioreactor 83](#_Toc123735361)

[FIGURE 7.4: Rocking Bioreactor 84](#_Toc123735362)

[FIGURE 7.5: Hollow Fiber Bioreactors 85](#_Toc123735363)

[FIGURE 7.6: Fixed-Bed Bioreactors 85](#_Toc123735364)

[FIGURE 7.7: Number of Cells per Batch by Technologies 93](#_Toc123735365)

[FIGURE 7.8: Single-Use Harvestainer for Small Scale Application 96](#_Toc123735366)

[FIGURE 7.9: Single-Use Harvestainer for Large Scale Application 97](#_Toc123735367)

[FIGURE 7.10: Advantages & Disadvantages of Autologous and Allogeneic MSC 100](#_Toc123735368)

[FIGURE 7.11: Cost of Goods (CoG) in MSC Manufacturing 103](#_Toc123735369)

[FIGURE 7.12: Impact of Headcount on Overall CoG per Batch 104](#_Toc123735370)

[FIGURE 7.13: CoG Breakdown in Partially-Automated MSC Manufacturing 105](#_Toc123735371)

[FIGURE 7.14: CoG Breakdown in Fully Automated MSC Manufacturing 106](#_Toc123735372)

[FIGURE 7.15: Higher Throughput in Partially Automated Facilities 107](#_Toc123735373)

[FIGURE 8.1: Schematic of Sartorius’ SelectT Automated Platform 112](#_Toc123735374)

[FIGURE 8.2: Model of a Clean Room in a Small Scale Manufacturing Facility 113](#_Toc123735375)

[FIGURE 9.1: Four Common Bioprocessing Strategies for Large-Scale Expansion of MSCs 116](#_Toc123735376)

[FIGURE 9.2: Commonly Used Sources of MSCs for Large-Scale Expansion 116](#_Toc123735377)

[FIGURE 9.3: Commonly used Culture Media for Large-Scale Expansion of MSCs 117](#_Toc123735378)

[FIGURE 10.1: Outsourced Percent of CGT Manufacturing: Now and Five Years from Now 121](#_Toc123735379)

[FIGURE 10.2: Number of CDMOs Utilized 122](#_Toc123735380)

[FIGURE 10.3: Major Services offered by CMOs 123](#_Toc123735381)

[FIGURE 10.4: Percentage of Total Biomanufacturing Capacity by Platform 125](#_Toc123735382)

[FIGURE 10.5: Global Bioprocessing Capacity by Region/Country 127](#_Toc123735383)

[FIGURE 10.6: U.K. Cleanroom Footprint for CGT Therapy Manufacturing, 20018-2022 132](#_Toc123735384)

[FIGURE 10.7: Cell Therapy Process Capabilities in the U.K. by Types of Process, 2022 133](#_Toc123735385)

[FIGURE 10.8: Gene Therapy Process Capabilities in the U.K. by Types of Process 134](#_Toc123735386)

[FIGURE 11.1: Major Diseases Addressed by MSCs in Clinical Trials 136](#_Toc123735387)

[FIGURE 11.2: Percent Share of Autoimmune Diseases Using MSCs in Clinical Trials 137](#_Toc123735388)

[FIGURE 11.3: Percent Share of MSCs by Source in Trials for Cardiac Diseases 138](#_Toc123735389)

[FIGURE 11.4: Percent Shares of Neurodegenerative Diseases in Clinical Trials using MSCs 139](#_Toc123735390)

[FIGURE 11.5: % Shares of Studies using MSCs in Bone & Cartilage Diseases by Source 140](#_Toc123735391)

[FIGURE 12.1: The Four MSC Modification Techniques 146](#_Toc123735392)

[FIGURE 13.2: Priming Effects on MSCs 148](#_Toc123735393)

[FIGURE 14.1: Percent Share of Marketed CT, GT and TE Products 174](#_Toc123735394)

[FIGURE 14.2: Percent Market Share of CT Products by Indication 175](#_Toc123735395)

[FIGURE 14.3: Global Market for MSC-Based Therapeutics by Geography 180](#_Toc123735396)

[FIGURE14.4: Global Market for MSCs by Geography, 2022-2030 183](#_Toc123735397)

[FIGURE 14.5: Market Share of MSCs by Business Segments 185](#_Toc123735398)

**INDEX OF TABLES**

[TABLE 2.1: Timeline of MSC Nomenclature 32](#_Toc123735402)

[TABLE 2.2: Sources of MSCs 33](#_Toc123735403)

[TABLE 2.3: Advantages and Disadvantages of BM-MSCs 34](#_Toc123735404)

[TABLE 2.4: Advantages and Disadvantages of AD-MSCs 34](#_Toc123735405)

[TABLE 2.5: Advantages and Disadvantages of UC-MSCs 35](#_Toc123735406)

[TABLE 2.6: Positive & Negative Markers in MSCs from different Sources 35](#_Toc123735407)

[TABLE 2.7: In Vitro Differentiation Potentials of MSCs 36](#_Toc123735408)

[TABLE 2.8: Soluble Factors Secreted by MSCs 37](#_Toc123735409)

[TABLE 2.8: (CONTINUED) 38](#_Toc123735410)

[TABLE 2.9: Some Typical Stemness Genes of MSCs 39](#_Toc123735411)

[TABLE 3.1: Number of Published Papers on MSCs between 2000 to Present 40](#_Toc123735412)

[TABLE 3.2: Number of Papers on MSCs & iPSCs Compared 42](#_Toc123735413)

[TABLE 3.3: Number of Papers Published on MSC-based Clinical Trials, 2000 to Present 43](#_Toc123735414)

[TABLE 3.4: Percent Share of Papers for Specific Diseases, 2000-2022 45](#_Toc123735415)

[TABLE 3.5: Published Papers on Modified MSCs 46](#_Toc123735416)

[TABLE 3.6: Number of PubMed Papers on MSC-Exosomes 48](#_Toc123735417)

[TABLE 4.1: Number of Patent Documents in Stem Cell Therapies 49](#_Toc123735418)

[TABLE 4.2: Top Ten Players in Stem Cell Patent Arena 51](#_Toc123735419)

[TABLE 4.3: Top Ten Stem Cell Patent Owners by Size of Patent Portfolio 53](#_Toc123735420)

[TABLE 4.4: Number of MSC Patent Filings by Year, 2000 to Present 53](#_Toc123735421)

[TABLE 4.5: Top Ten MSC Patent Applicants 54](#_Toc123735422)

[TABLE 4.6: Status of MSC Patent Applications, 2000-2022 55](#_Toc123735423)

[TABLE 4.7: MSC Patent Jurisdictions 55](#_Toc123735424)

[TABLE 4.7: (CONTINUED) 56](#_Toc123735425)

[TABLE 4.8: Top Ten MSC Patent Inventors 56](#_Toc123735426)

[TABLE 4.9: Top Ten MSC Patent Owners 57](#_Toc123735427)

[TABLE 4.10: Top Ten MSC-Exosome Patent Applicants 58](#_Toc123735428)

[TABLE 4.11: MSC-Exosomes Patent Jurisdiction 59](#_Toc123735429)

[TABLE 4.12: Top Ten MSC-Exosome Patent Inventors 59](#_Toc123735430)

[TABLE 5.1: Number of Clinical Trials involving MSCs by Region 61](#_Toc123735431)

[TABLE 5.2: Sources of MSCs for Clinical Trials 62](#_Toc123735432)

[TABLE 5.3: Clinical Trials involving Autologous and Allogneic MSCs in 2022 63](#_Toc123735433)

[TABLE 5.4: Types of Funding for MSC-based Clinical Trials 64](#_Toc123735434)

[TABLE 5.5: Types of MSC-based Clinical Trials 65](#_Toc123735435)

[TABLE 5.6: MSC-based Clinical Trials by Phase of Development 66](#_Toc123735436)

[TABLE 5.7: Examples of MSC-based Clinical Trials for Musculoskeletal Disorders 68](#_Toc123735437)

[TABLE 5.7: (CONTINUED) 69](#_Toc123735438)

[TABLE 5.8: MSC-based Clinical Trials for Neurological Disorders 70](#_Toc123735439)

[TABLE 5.9: Clinical Trials involving MSC-derived Exosomes 71](#_Toc123735440)

[TABLE 6.1: Examples of Bioengineered MSCs as Living Drug Factories 75](#_Toc123735441)

[TABLE 6.2: Examples of Oncology Indications being studied using MSC Trojan Horses 76](#_Toc123735442)

[TABLE 6.3: Select Cases of Modified MSC Applications & Therapeutic Outcome 78](#_Toc123735443)

[TABLE 7.1: Methods of Isolation of MSCs & Corresponding Culture Media 81](#_Toc123735444)

[TABLE 7.2: A Snapshot of Commercially Available Culture Systems 87](#_Toc123735445)

[TABLE 7.2: (CONTINUED) 88](#_Toc123735446)

[TABLE 7.2: (CONTINUED) 89](#_Toc123735447)

[TABLE 7.2: (CONTINUED) 90](#_Toc123735448)

[TABLE 7.2: (CONTINUED) 91](#_Toc123735449)

[TABLE 7.3: Main Features of Commercially Available Bioreactors 92](#_Toc123735450)

[TABLE 7.4: Microcarriers for the Expansion of MSCs 94](#_Toc123735451)

[TABLE 7.4: (CONTINUED) 95](#_Toc123735452)

[TABLE 7.5: Basic Assays for MSCs 98](#_Toc123735453)

[TABLE 7.6: Cell Surface Markers on MSCs and Fibroblasts 99](#_Toc123735454)

[TABLE 7.7: Cost of Manufacturing Allogeneic MSCs 100](#_Toc123735455)

[TABLE 7.8: Cost of Manufacturing Autologous MSCs 101](#_Toc123735456)

[TABLE 7.9: Cost of Goods (CoG) in MSC Manufacturing 102](#_Toc123735457)

[TABLE 7.10: CoG Breakdown in Partially-Automated MSC Manufacturing 105](#_Toc123735458)

[TABLE 7.11: CoG Breakdown in Fully Automated MSC Manufacturing 106](#_Toc123735459)

[TABLE 7.12: Higher Throughput in Partially Automated Facilities 107](#_Toc123735460)

[TABLE 8.1: Key Processes and Cost Assumptions 109](#_Toc123735461)

[TABLE 8.2: Quality Control Panels and Cost Assumptions 110](#_Toc123735462)

[TABLE 8.3: Additional Supporting Labor Cost Assessments 110](#_Toc123735463)

[TABLE 8.3: (CONTINUED) 111](#_Toc123735464)

[TABLE 8.4: Additional Supporting Facility and Cost Assumptions 111](#_Toc123735465)

[TABLE 8.4: (CONTINUED) 112](#_Toc123735466)

[TABLE 9.1: Large-Scale Expansion of MSCs by Method, Cell Source and Media 114](#_Toc123735467)

[TABLE 9.1: (CONTINUED) 115](#_Toc123735468)

[TABLE 9.2: Expansion Ratios Achieved with Different Culture Media 118](#_Toc123735469)

[TABLE 9.3: Comparison between the Four Large-Scale MSC Expansion Strategies 119](#_Toc123735470)

[TABLE 10.1: Comparison of Capacity Trends, 2018-2021 125](#_Toc123735471)

[TABLE 10.2: Current Distribution of Capacity by Facility Size 126](#_Toc123735472)

[TABLE 10.3: Global Bioprocessing Capacity by Region/Country 127](#_Toc123735473)

[TABLE 10.4: Top Global CDMOs 128](#_Toc123735474)

[TABLE 10.5: GMP Capacities of U.S-based Contract Manufacturers 129](#_Toc123735475)

[TABLE 10.6: Major Cell & Gene Therapy Contract Manufacturers in Europe 129](#_Toc123735476)

[TABLE 10.7: GMP Manufacturing Facilities for Cell and Gene Therapies in U.K., 2022 130](#_Toc123735477)

[TABLE 10.7: (CONTINUED) 131](#_Toc123735478)

[TABLE 10.8: U.K. Cleanroom Footprint for Cell & Gene Therapy Manufacturing, 20018-2022 132](#_Toc123735479)

[TABLE 10.9: Countries Outsourcing Cell & Gene Therapy Services from U.K. by Country 135](#_Toc123735480)

[TABLE 11.1: Select MSC-Based Clinical Trials for Autoimmune Diseases 137](#_Toc123735481)

[TABLE 11.2: Select MSC-Based Clinical Trials for Cardiovascular Studies 138](#_Toc123735482)

[TABLE 11.3: Select MSC-Based Studies using MSCs for Neurodegenerative Diseases 139](#_Toc123735483)

[TABLE 11.4: Select MSC-Based Studies for Bone & Cartilage Diseases 140](#_Toc123735484)

[TABLE 11.5: Ongoing Studies using MSCs for GvHD 141](#_Toc123735485)

[TABLE 11.6: Examples of Ongoing Clinical Trials using MSCs for Crohn’s Disease 141](#_Toc123735486)

[TABLE 11.7: Examples of Ongoing Clinical Trials using MSCs for Type 1 Diabetes 142](#_Toc123735487)

[TABLE 11.8: Examples of Currently Ongoing Clinical Trials using MSCs for SLE 142](#_Toc123735488)

[TABLE 11.9: Examples of Ongoing Clinical Trials using MSCs for PD 143](#_Toc123735489)

[TABLE 11.10: Examples of Currently Ongoing Clinical Trials using MSCs for AD 143](#_Toc123735490)

[TABLE 11.11: Examples of Ongoing Clinical Trials using MSCs for Kidney Failure 144](#_Toc123735491)

[TABLE 11.12: Examples of Ongoing Clinical Trials using MSCs for SCI 144](#_Toc123735492)

[TABLE 11.13: Examples of Currently Ongoing Clinical Trials using MSCs for SCI 145](#_Toc123735493)

[TABLE 12.1: Clinical Trials Involving Engineered MSCs 147](#_Toc123735494)

[TABLE 12.2: Primed MSCs in Clinical Trials 149](#_Toc123735495)

[TABLE 12.3: Scaffold-Based MSCs in Clinical Trials 149](#_Toc123735496)

[TABLE 12.3: (CONTINUED) 150](#_Toc123735497)

[TABLE 12.4: Clinical Trials Involving MSC-Derived Exosomes 151](#_Toc123735498)

[TABLE 12.5: Commercially Available Products Incorporated with Secretomes 152](#_Toc123735499)

[TABLE 12.5: (CONTINUED) 153](#_Toc123735500)

[TABLE 12.5: (CONTINUED) 154](#_Toc123735501)

[TABLE 12.6: MSC Products with Marketing Approval 155](#_Toc123735502)

[TABLE 12.6: (CONTINUED) 156](#_Toc123735503)

[TABLE 12.7: Marketed MSC-Containing Bone Matrices 160](#_Toc123735504)

[TABLE 14.1: Price Tags of MSC-Based Approved CT Products 176](#_Toc123735505)

[TABLE 14.2: Price Tags of Select MSC Progenitor-Based Products 177](#_Toc123735506)

[TABLE 14.3: Global Market for MSC-Based Therapeutics 180](#_Toc123735507)

[TABLE 14.4: Global Market for MSCs by Geography, 2022-2030 183](#_Toc123735508)

[TABLE 15.1: Ambulero’s Product Pipeline 202](#_Toc123735509)

[TABLE 15.2: BioCardia’s Advanced Pipeline 219](#_Toc123735510)

[TABLE 15.3: Bonus Biogroup’s Product Pipeline 228](#_Toc123735511)

[TABLE 15.4: BrainStorm’s Product Pipeline 229](#_Toc123735512)

[TABLE 15.5: CardioCell’s Clinical Development 232](#_Toc123735513)

[TABLE 15.6: Celltex’s Clinical Trials 239](#_Toc123735514)

[TABLE 15.7: Corestem’s Product Pipeline 243](#_Toc123735515)

[TABLE 15.8: Cynata’s Product Pipeline 248](#_Toc123735516)

[TABLE 15.9: Regulatory Proteins found in ExoFlo 253](#_Toc123735517)

[TABLE 15.10: Hope’s Clinical Trial Pipeline 265](#_Toc123735518)

[TABLE 15.11: Growth Factors in XoGlo and XoGlo Plus 271](#_Toc123735519)

[TABLE 15.12: Mesoblast’s Late-Stage Clinical Pipeline 288](#_Toc123735520)

[TABLE 15.13: Pluristem’s Clinical Pipeline 304](#_Toc123735521)

[TABLE 15.14: Regeneus’ Product Pipeline 307](#_Toc123735522)

[TABLE 15.15: Sentien’s Product Pipeline 323](#_Toc123735523)

[TABLE 15.16: Stemedica’s Clinical Pipeline 327](#_Toc123735524)

[TABLE 15.17: Stempeutics’ Product Candidates in Clinical Trial 331](#_Toc123735525)

About BioInformant:

As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine.

Serving Fortune 500 companies that include Pfizer, GE Healthcare, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.

To learn more, visit BioInformant.com.

**BioInformant Worldwide, LLC**

**BioInformant.com**